Highlight
- Sotatercept significantly reduces pulmonary vascular resistance and mean pulmonary artery pressure, improving right ventricular-pulmonary artery (RV-PA) coupling in patients with pulmonary arterial hypertension (PAH).
- Systemic decongestion by sotatercept leads to hemoconcentration, elevating hemoglobin concentration without increasing red cell mass, thereby enhancing oxygen transport capacity.
- Despite a reduction in resting cardiac output (CO), sotatercept increases CO reserve during exercise, which correlates strongly with improved peak oxygen consumption and aerobic capacity.
- Skeletal muscle oxygen delivery and utilization are enhanced after sotatercept treatment, contributing to improved peripheral oxygen extraction and single-leg exercise performance.
Specialty calculators
For clinical reference; use professional judgment.
